Corcept Therapeutics Inc

CORT's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

CORT Growth rates comparisons

Looking into Corcept Therapeutics Inc growth rates, revenue grew by 18.7 % in the second quarter of 2025 from the same quarter a year ago. Ranking at No. 772

Major Pharmaceutical Preparations industry recorded growth of revenues by 8.14 %

Corcept Therapeutics Inc's net profit decreased by -1.45 % in second quarter of 2025 year on year, to $35 millions.

• More on CORT's Growth

CORT's Valuation comparisons

Corcept Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Corcept Therapeutics Inc realized cash reduction of $ -0.21 per share in trailing twelve-month period.

Company

66.23

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 12.48.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

• More on CORT's Valuation

Total Debt (Millions $)	-
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	2,034,318
Net Income/Employee (TTM) $	374,994
Receivable Turnover (TTM)	11.93
Tangible Book Value (Per Share $)	5.28

CORT's Valuation comparisons

Corcept Therapeutics Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Corcept Therapeutics Inc realized cash outflow of $ -0.21per share in trailing twelve-month period.

Company

66.23

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 12.48.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

Corcept Therapeutics Inc Price to Book Ratio is at 14.06 lower than Industry Avg. of 39.17. and higher than S&P 500 Avg. of 0.02

• More on CORT's Valuation

• Market Capitalization (Millions $)	8,936
• Shares Outstanding (Millions)	120
• Employees	352
• Revenues (TTM) (Millions $)	716
• Net Income (TTM) (Millions $)	132
• Cash Flow (TTM) (Millions $)	-26
• Capital Exp. (TTM) (Millions $)	-2
• Total Debt (Millions $)	-
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	2,034,318
• Net Income/Employee(TTM) $	374,994
• Receivable Turnover Ratio (TTM)	11.93
• Tangible Book Value (Per Share $)	5.28

• Market Capitalization (Millions $)	8,936
• Shares Outstanding (Millions)	120
• Employees	352
• Revenues (TTM) (Millions $)	716
• Net Income (TTM) (Millions $)	132
• Cash Flow (TTM) (Millions $)	-26
• Capital Exp. (TTM) (Millions $)	-2

CORT's Profitability Comparisons

Corcept Therapeutics Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in second quarter of 2025 to 13.72 % from 2.17 % in I. Quarter.

Corcept Therapeutics Inc net profit margin of 17.8 % is currently ranking no. 34 in Major Pharmaceutical Preparations industry, ranking no. 70 in Healthcare sector and number 816 in S&P 500.

Profitability by Segment
Total	17.8 %

	*Ratio*
• Capital Ratio (MRQ)	3.06
• Total Debt to Equity (MRQ)	-
• Tangible Leverage Ratio (MRQ)	0.26
• Asset Turnover Ratio (TTM)	1.06
• Inventory Turnover Ratio (TTM)	0.99

CORT's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.